These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 17023833)

  • 1. Antitumor activity of nifurtimox observed in a patient with neuroblastoma.
    Saulnier Sholler GL; Kalkunte S; Greenlaw C; McCarten K; Forman E
    J Pediatr Hematol Oncol; 2006 Oct; 28(10):693-5. PubMed ID: 17023833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1 study of nifurtimox in patients with relapsed/refractory neuroblastoma.
    Saulnier Sholler GL; Bergendahl GM; Brard L; Singh AP; Heath BW; Bingham PM; Ashikaga T; Kamen BA; Homans AC; Slavik MA; Lenox SR; Higgins TJ; Ferguson WS
    J Pediatr Hematol Oncol; 2011 Jan; 33(1):25-30. PubMed ID: 21063221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.
    Hunold A; Weddeling N; Paulussen M; Ranft A; Liebscher C; Jürgens H
    Pediatr Blood Cancer; 2006 Nov; 47(6):795-800. PubMed ID: 16411206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults.
    Kushner BH; Cheung NK; Kramer K; Dunkel IJ; Calleja E; Boulad F
    Bone Marrow Transplant; 2001 Sep; 28(6):551-6. PubMed ID: 11607767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma.
    Garaventa A; Luksch R; Biasotti S; Severi G; Pizzitola MR; Viscardi E; Prete A; Mastrangelo S; Podda M; Haupt R; De Bernardi B
    Cancer; 2003 Dec; 98(11):2488-94. PubMed ID: 14635085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroblastoma.
    Meir HM; Balawi I; Nayel H; Yousef MK; Badawood S; Al-Mobarak M
    Saudi Med J; 2001 Aug; 22(8):674-80. PubMed ID: 11573111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma.
    Kushner BH; Kramer K; Modak S; Qin LX; Cheung NK
    Cancer; 2010 Jun; 116(12):3054-60. PubMed ID: 20564411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adeno-associated virus vector-mediated systemic delivery of IFN-beta combined with low-dose cyclophosphamide affects tumor regression in murine neuroblastoma models.
    Streck CJ; Dickson PV; Ng CY; Zhou J; Gray JT; Nathwani AC; Davidoff AM
    Clin Cancer Res; 2005 Aug; 11(16):6020-9. PubMed ID: 16115947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Nifurtimox, a bright future for treatment of Chagas disease].
    Wolf A; Boulliat C; Coillot C; Rouault M; Gaillard K; Beranger C; Oliver M
    Med Trop (Mars); 2011 Apr; 71(2):131-3. PubMed ID: 21695868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
    Peng H; Sohara Y; Moats RA; Nelson MD; Groshen SG; Ye W; Reynolds CP; DeClerck YA
    Cancer Res; 2007 Oct; 67(19):9346-55. PubMed ID: 17909043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topotecan plus cyclophosphamide as maintenance chemotherapy for children with high-risk neuroblastoma in complete remission: short-term curative effects and toxicity.
    Feng C; Tang S; Wang J; Liu Y; Yang G
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Aug; 33(8):1107-10. PubMed ID: 23996746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma.
    De Bernardi B; Nicolas B; Boni L; Indolfi P; Carli M; Cordero Di Montezemolo L; Donfrancesco A; Pession A; Provenzi M; di Cataldo A; Rizzo A; Tonini GP; Dallorso S; Conte M; Gambini C; Garaventa A; Bonetti F; Zanazzo A; D'Angelo P; Bruzzi P;
    J Clin Oncol; 2003 Apr; 21(8):1592-601. PubMed ID: 12697885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy.
    Mastrangelo S; Tornesello A; Diociaiuti L; Pession A; Prete A; Rufini V; Troncone L; Mastrangelo R
    Br J Cancer; 2001 Feb; 84(4):460-4. PubMed ID: 11207038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response of metastatic recurrent neuroblastoma to nitisinone: a modulator of tyrosine metabolism.
    Kobrinsky NL; Sjolander DE
    Pediatr Blood Cancer; 2006 Apr; 46(4):517-20. PubMed ID: 15940725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.
    Cheung NK; Kushner BH; LaQuaglia M; Kramer K; Gollamudi S; Heller G; Gerald W; Yeh S; Finn R; Larson SM; Wuest D; Byrnes M; Dantis E; Mora J; Cheung IY; Rosenfield N; Abramson S; O'Reilly RJ
    Med Pediatr Oncol; 2001 Jan; 36(1):227-30. PubMed ID: 11464891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
    Horibe K; Fukuda M; Miyajima Y; Matsumoto K; Kondo M; Inaba J; Miyashita Y
    Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol.
    Valteau-Couanet D; Michon J; Boneu A; Rodary C; Perel Y; Bergeron C; Rubie H; Coze C; Plantaz D; Bernard F; Chastagner P; Bouzy J; Hartmann O
    J Clin Oncol; 2005 Jan; 23(3):532-40. PubMed ID: 15659499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of chemotherapy regimen using ifosphamide and carboplatin on recurrent or refractory neuroblastoma].
    Zhen ZJ; Sun XF; Xia Y; Wang ZH; Ling JY
    Ai Zheng; 2006 Dec; 25(12):1550-2. PubMed ID: 17166384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy.
    Kushner BH; Cheung IY; Kramer K; Modak S; Cheung NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):430-4. PubMed ID: 16421906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.